T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 |
Tesla
TSLA
|
+$1.87B |
| 2 |
T-Mobile US
TMUS
|
+$1.53B |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.43B |
| 4 |
Apple
AAPL
|
+$1.28B |
| 5 |
PepsiCo
PEP
|
+$1.1B |
Top Sells
| 1 |
Alphabet (Google) Class C
GOOG
|
+$3.16B |
| 2 |
Amazon
AMZN
|
+$3.02B |
| 3 |
GE Aerospace
GE
|
+$2.2B |
| 4 |
Goldman Sachs
GS
|
+$1.76B |
| 5 |
Salesforce
CRM
|
+$1.43B |
Sector Composition
| 1 | Technology | 30.27% |
| 2 | Healthcare | 17.75% |
| 3 | Financials | 11.3% |
| 4 | Consumer Discretionary | 11.17% |
| 5 | Communication Services | 8.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
826
Agios Pharmaceuticals
AGIO
$2.13B
| $29M | ﹤0.01% |
1,263,697
-216,497
| -15% | -$4.97M |
|
827
Monte Rosa Therapeutics
GLUE
$305M
| $28.8M | ﹤0.01% |
3,693,494
+10,064
| +0.3% | +$78.4K |
|
828
Element Solutions
ESI
$6.33B
| $28.7M | ﹤0.01% |
1,488,144
-2,723,941
| -65% | -$52.6M |
|
829
Allegiant Air
ALGT
$1.18B
| $28.6M | ﹤0.01% |
311,406
+8,603
| +3% | +$791K |
|
830
Clorox
CLX
$15.2B
| $28.6M | ﹤0.01% |
180,811
+7,226
| +4% | +$1.14M |
|
831
ATI
ATI
$10.4B
| $28.1M | ﹤0.01% |
712,994
+662,166
| +1,303% | +$26.1M |
|
|
ENV
832
DELISTED
ENVESTNET, INC.
ENV
| $28M | ﹤0.01% |
477,876
-15,563
| -3% | -$913K |
|
833
XPO
XPO
$15.9B
| $27.9M | ﹤0.01% |
874,667
+45,896
| +6% | +$1.46M |
|
834
Hewlett Packard
HPE
$32.6B
| $27.8M | ﹤0.01% |
1,743,273
+23,590
| +1% | +$376K |
|
|
BKI
835
DELISTED
Black Knight, Inc. Common Stock
BKI
| $27.8M | ﹤0.01% |
482,430
-4,706,855
| -91% | -$271M |
|
836
Concentrix
CNXC
$3.31B
| $27.7M | ﹤0.01% |
227,475
-77,251
| -25% | -$9.39M |
|
837
ICU Medical
ICUI
$3.33B
| $27.6M | ﹤0.01% |
167,112
-58,146
| -26% | -$9.59M |
|
838
PPL Corp
PPL
$26.6B
| $27.4M | ﹤0.01% |
987,383
+30,066
| +3% | +$836K |
|
839
Flowserve
FLS
$7.48B
| $27.4M | ﹤0.01% |
806,188
-147,180
| -15% | -$5M |
|
840
Evolent Health
EVH
$1.08B
| $27.4M | ﹤0.01% |
843,944
-3,185
| -0.4% | -$103K |
|
|
RETA
841
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $27M | ﹤0.01% |
297,065
+277,696
| +1,434% | +$25.2M |
|
842
Labcorp
LH
$23.1B
| $27M | ﹤0.01% |
136,917
-21,595
| -14% | -$4.26M |
|
|
DHR.PRB
843
DELISTED
Danaher Corporation 5.00% Mandatory Convertible Preferred Stock, Series B
DHR.PRB
| – | – |
0
| – | -$47.4M |
|
844
Skyward Specialty Insurance
SKWD
$1.93B
| $26.9M | ﹤0.01% |
+1,230,449
| New | +$26.9M |
|
845
FormFactor
FORM
$2.33B
| $26.9M | ﹤0.01% |
844,012
-142,970
| -14% | -$4.55M |
|
846
Tradeweb Markets
TW
$25.4B
| $26.7M | ﹤0.01% |
337,446
-28,594
| -8% | -$2.26M |
|
847
CureVac
CVAC
$1.22B
| $26.6M | ﹤0.01% |
3,813,896
+3,260,031
| +589% | +$22.7M |
|
848
Nasdaq
NDAQ
$54.9B
| $26.2M | ﹤0.01% |
479,123
-95,044
| -17% | -$5.2M |
|
849
Lumentum
LITE
$11.5B
| $26.2M | ﹤0.01% |
484,398
-19,333
| -4% | -$1.04M |
|
850
Celldex Therapeutics
CLDX
$1.69B
| $25.7M | ﹤0.01% |
713,562
-119,447
| -14% | -$4.3M |
|